CryositeASX:CTE 51 Gross Margin % is 61.50% as of Dec. 2025, which is 13% above its 10-year median of 54.58. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 195 Medical Diagnostics & Research companies, Cryosite ranks better than 64.62% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Cryosite's Gross Profit for the
six
months ended in Dec. 2025 was A$5.09 Mil. Cryosite's Revenue for the
six
months ended in Dec. 2025 was A$8.27 Mil. Therefore, Cryosite's Gross Margin % for the quarter that ended in Dec. 2025 was 61.50%.
The historical rank and industry rank for Cryosite's Gross Margin % or its related term are showing as below:
ASX:CTE'
s Gross Margin % Range Over the Past 10 Years
Min: 38.17 Med: 54.58 Max: 63.38
Current: 61.76
During the past 13 years, the highestGross Margin % of Cryosite was 63.38%. The lowest was 38.17%. And the median was 54.58%.
ASX:CTE's Gross Margin % is ranked better than 64.62% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs ASX:CTE: 61.76
Cryosite had a gross margin of 61.50% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cryosite was 6.00% per year.
Cryosite (ASX:CTE) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cryosite had a gross margin of 61.50% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cryosite Gross Margin % Related Terms
Cryosite Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cryosite's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Cryosite's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cryosite's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cryosite (ASX:CTE) has a Gross Margin % of 61.50% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Cryosite and its competitors. This is 13% above median its historical median of 54.58. Over the past decade, Cryosite's Gross Margin % has ranged from 38.17 to 63.38. According to the industry distribution chart, Cryosite ranks #69 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 35.4%.
Is Cryosite's Gross Margin % too high?
Cryosite's current Gross Margin % of 61.50% is 13% above median its 10-year median of 54.58. Over the past 10 years, this metric has ranged from a low of 38.17 to a high of 63.38. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Cryosite's value of 61.50% is 20.7% above this industry median. Based on the distribution chart, Cryosite ranks #69 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #69 out of 195 companies for Gross Margin %. This puts Cryosite in the upper half of its industry. The industry median Gross Margin % is 50.97. Cryosite's value of 61.50% is 20.7% above this benchmark. Historically, Cryosite's own Gross Margin % has ranged from 38.17 to 63.38 over the past decade. While the company's 10-year median is 54.58 vs. the industry median of 50.97, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current Gross Margin % of 61.50% is 20.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current Gross Margin % is 61.50%, which is 13% above median its own 10-year median of 54.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Gross Margin % is 61.50%, which is 13% above median its 10-year median of 54.58 and 20.7% above the Medical Diagnostics & Research industry median of 50.97. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Gross Margin % is 61.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
Gross Margin %: 61.50% (13% above median its 10-year median of 54.58)
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
Industry Position: 20.7% above the Medical Diagnostics & Research median (#69 of 195)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
